Title:
TRIM51 BIOMARKER FOR PREDICTING MELANOMA TREATMENT RESISTANCE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/149608
Kind Code:
A1
Abstract:
The present invention relates to a TRIM51 biomarker for predicting melanoma treatment resistance and a use thereof. As a result of verifying the effectiveness as a candidate for overcoming melanoma drug resistance through the regulation of TRIM51 mRNA or protein, and confirming whether it shows clinical significance as a treatment response prediction marker, melanoma-derived TRIM51 is very likely to find advantageous applications as a biomarker for predicting melanoma treatment response.
Inventors:
LIM BYUNG HO (KR)
CHOI GIL DON (KR)
CHO KYUNG JIN (KR)
CHOI GIL DON (KR)
CHO KYUNG JIN (KR)
Application Number:
PCT/KR2022/011017
Publication Date:
August 10, 2023
Filing Date:
July 27, 2022
Export Citation:
Assignee:
KOREA RES INST CHEMICAL TECH (KR)
International Classes:
C12Q1/6886
Foreign References:
| KR20180099123A | 2018-09-05 | |||
| KR20210114219A | 2021-09-23 | |||
| KR20210114877A | 2021-09-24 |
Other References:
ZHANG XIU-ZHONG, LI FU-HUANG, WANG XIAO-JIA: "Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion", FRONTIERS IN MICROBIOLOGY, vol. 12, XP093082599, DOI: 10.3389/fmicb.2021.794882
LIM BYUNGHO: "The role of TRIM51 as a multipurpose biomarker in melanoma", TRANSLATIONAL CANCER RESEARCH, vol. 10, no. 10, 1 October 2021 (2021-10-01), pages 4327 - 4337, XP093082602, ISSN: 2218-676X, DOI: 10.21037/tcr-21-1102
LIM BYUNGHO: "The role of TRIM51 as a multipurpose biomarker in melanoma", TRANSLATIONAL CANCER RESEARCH, vol. 10, no. 10, 1 October 2021 (2021-10-01), pages 4327 - 4337, XP093082602, ISSN: 2218-676X, DOI: 10.21037/tcr-21-1102
Attorney, Agent or Firm:
ISIS IP LAW LLC (KR)
Download PDF: